Cargando…
Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122884/ https://www.ncbi.nlm.nih.gov/pubmed/33922585 http://dx.doi.org/10.3390/ijms22094420 |
_version_ | 1783692744019935232 |
---|---|
author | Mahjoubin-Tehran, Maryam Teng, Yong Jalili, Amin Aghaee-Bakhtiari, Seyed Hamid Markin, Alexander M. Sahebkar, Amirhossein |
author_facet | Mahjoubin-Tehran, Maryam Teng, Yong Jalili, Amin Aghaee-Bakhtiari, Seyed Hamid Markin, Alexander M. Sahebkar, Amirhossein |
author_sort | Mahjoubin-Tehran, Maryam |
collection | PubMed |
description | Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings. |
format | Online Article Text |
id | pubmed-8122884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81228842021-05-16 Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis Mahjoubin-Tehran, Maryam Teng, Yong Jalili, Amin Aghaee-Bakhtiari, Seyed Hamid Markin, Alexander M. Sahebkar, Amirhossein Int J Mol Sci Review Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings. MDPI 2021-04-23 /pmc/articles/PMC8122884/ /pubmed/33922585 http://dx.doi.org/10.3390/ijms22094420 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mahjoubin-Tehran, Maryam Teng, Yong Jalili, Amin Aghaee-Bakhtiari, Seyed Hamid Markin, Alexander M. Sahebkar, Amirhossein Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title | Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title_full | Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title_fullStr | Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title_full_unstemmed | Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title_short | Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis |
title_sort | decoy technology as a promising therapeutic tool for atherosclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122884/ https://www.ncbi.nlm.nih.gov/pubmed/33922585 http://dx.doi.org/10.3390/ijms22094420 |
work_keys_str_mv | AT mahjoubintehranmaryam decoytechnologyasapromisingtherapeutictoolforatherosclerosis AT tengyong decoytechnologyasapromisingtherapeutictoolforatherosclerosis AT jaliliamin decoytechnologyasapromisingtherapeutictoolforatherosclerosis AT aghaeebakhtiariseyedhamid decoytechnologyasapromisingtherapeutictoolforatherosclerosis AT markinalexanderm decoytechnologyasapromisingtherapeutictoolforatherosclerosis AT sahebkaramirhossein decoytechnologyasapromisingtherapeutictoolforatherosclerosis |